Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2015 06:00 ET | Source: Mesoblast Limited

Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease

MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received...
October 22, 2015 02:00 ET | Source: Mesoblast

Mesoblast Chairman's Address to 2015 Annual General Meeting

NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting. This has been another exciting and productive year in the history of our...
September 03, 2015 20:44 ET | Source: Mesoblast

Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan

NEW YORK and MELBOURNE, Australia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine...
August 16, 2015 20:28 ET | Source: Mesoblast

Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program

NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...
September 30, 2014 20:17 ET | Source: Mesoblast

Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan

NEW YORK and MELBOURNE, Australia, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR...
April 28, 2014 21:51 ET | Source: Mesoblast

Mesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, April 28, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the...
November 24, 2013 19:16 ET | Source: Mesoblast

New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products

NEW YORK and MELBOURNE, Australia, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a...